Skip to main content
Premium Trial:

Request an Annual Quote

Applied DNA Sciences Gets Conditional NY State Approval for COVID-19 Test

NEW YORK — Applied DNA Sciences said on Tuesday that it has received conditional approval from the New York State Department of Health for its Linea 2.0 COVID-19 assay as a laboratory-developed test.

Although a final review of the assay's validation data by the NYSDOH is pending, the conditional approval — which covers testing in individuals, as well as pooled testing with up to five samples — allows Applied DNA to roll out the RT-PCR-based test to support clients of New York state's SafeCircle program for the diagnostic testing of COVID-19, the company said.

Stony Brook, New York-based Applied DNA said it also intends to submit the Linea 2.0 assay, along with an unsupervised, at-home sample collection kit, for Emergency Use Authorization from the US Food and Drug Administration.

The Linea 2.0 test is designed to detect conserved regions of the SARS-CoV-2 E and N genes in respiratory samples. It is a next-generation version of the company's Linea assay, which detects the SARS-CoV-2 S gene and received EUA from the FDA in mid-2020.

Last year, Applied DNA's Applied DNA Clinical Labs subsidiary received CLIA certification from the NYSDOH, allowing it to perform high-throughput SARS-CoV-2 testing.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.